Candrika D. Khairani , Antoine Bejjani , Ali Assi , Nicole Porio , Azita H. Talasaz , Gregory Piazza , Mary Cushman , Behnood Bikdeli
{"title":"治疗静脉血栓的直接口服抗凝剂:适当使用的图解回顾","authors":"Candrika D. Khairani , Antoine Bejjani , Ali Assi , Nicole Porio , Azita H. Talasaz , Gregory Piazza , Mary Cushman , Behnood Bikdeli","doi":"10.1016/j.rpth.2024.102424","DOIUrl":null,"url":null,"abstract":"<div><p>Direct oral anticoagulants (DOACs) have become the preferred option for treatment of venous thromboembolism due to their favorable profile compared with other agents such as vitamin K antagonists or low-molecular-weight heparin. However, findings from randomized controlled trials suggest efficacy and/or safety concerns with DOAC use in some clinical contexts. This illustrated review will summarize indications where DOACs have proven efficacy and safety, situations where they fall short, and situations where uncertainty remains compared with other treatments for venous thromboembolism.</p></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2475037924001134/pdfft?md5=1f0a0b11223c3588142f79399092b85e&pid=1-s2.0-S2475037924001134-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Direct oral anticoagulants for treatment of venous thrombosis: illustrated review of appropriate use\",\"authors\":\"Candrika D. Khairani , Antoine Bejjani , Ali Assi , Nicole Porio , Azita H. Talasaz , Gregory Piazza , Mary Cushman , Behnood Bikdeli\",\"doi\":\"10.1016/j.rpth.2024.102424\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Direct oral anticoagulants (DOACs) have become the preferred option for treatment of venous thromboembolism due to their favorable profile compared with other agents such as vitamin K antagonists or low-molecular-weight heparin. However, findings from randomized controlled trials suggest efficacy and/or safety concerns with DOAC use in some clinical contexts. This illustrated review will summarize indications where DOACs have proven efficacy and safety, situations where they fall short, and situations where uncertainty remains compared with other treatments for venous thromboembolism.</p></div>\",\"PeriodicalId\":20893,\"journal\":{\"name\":\"Research and Practice in Thrombosis and Haemostasis\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2475037924001134/pdfft?md5=1f0a0b11223c3588142f79399092b85e&pid=1-s2.0-S2475037924001134-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Research and Practice in Thrombosis and Haemostasis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2475037924001134\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research and Practice in Thrombosis and Haemostasis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2475037924001134","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
与维生素 K 拮抗剂或低分子量肝素等其他药物相比,直接口服抗凝血剂(DOACs)具有良好的特性,因此已成为治疗静脉血栓栓塞症的首选药物。然而,随机对照试验的结果表明,在某些临床情况下使用 DOAC 存在疗效和/或安全性方面的问题。这篇图文并茂的综述将总结 DOAC 经证实具有疗效和安全性的适应症、DOAC 不足之处以及与其他静脉血栓栓塞治疗方法相比仍存在不确定性的情况。
Direct oral anticoagulants for treatment of venous thrombosis: illustrated review of appropriate use
Direct oral anticoagulants (DOACs) have become the preferred option for treatment of venous thromboembolism due to their favorable profile compared with other agents such as vitamin K antagonists or low-molecular-weight heparin. However, findings from randomized controlled trials suggest efficacy and/or safety concerns with DOAC use in some clinical contexts. This illustrated review will summarize indications where DOACs have proven efficacy and safety, situations where they fall short, and situations where uncertainty remains compared with other treatments for venous thromboembolism.